Drug Safety Matters podcast

Player FM - Internet Radio Done Right

Dodano five lat temu

Treść dostarczona przez Uppsala Monitoring Centre. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez Uppsala Monitoring Centre lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.

All About Change

1
Eli Beer & United Hatzalah: Saving Lives in 90 seconds or Less 30:20

10 dni temu30:20

Na później

Listy

Polub

Polubione

30:20

Eli Beer is a pioneer, social entrepreneur, President and Founder of United Hatzalah of Israel. In thirty years, the organization has grown to more than 6,500 volunteers who unite together to provide immediate, life-saving care to anyone in need - regardless of race or religion. This community EMS force network treats over 730,000 incidents per year, in Israel, as they wait for ambulances and medical attention. Eli’s vision is to bring this life-saving model across the world. In 2015, Beer expanded internationally with the establishment of branches in South America and other countries, including “United Rescue” in Jersey City, USA, where the response time was reduced to just two minutes and thirty-five seconds. Episode Chapters (0:00) intro (1:04) Hatzalah’s reputation for speed (4:48) Hatzalah’s volunteer EMTs and ambucycles (5:50) Entrepreneurism at Hatzalah (8:09) Chutzpah (14:15) Hatzalah’s recruitment (18:31) Volunteers from all walks of life (22:51) Having COVID changed Eli’s perspective (26:00) operating around the world amid antisemitism (28:06) goodbye For video episodes, watch on www.youtube.com/@therudermanfamilyfoundation Stay in touch: X: @JayRuderman | @RudermanFdn LinkedIn: Jay Ruderman | Ruderman Family Foundation Instagram: All About Change Podcast | Ruderman Family Foundation To learn more about the podcast, visit https://allaboutchangepodcast.com/ Looking for more insights into the world of activism? Be sure to check out Jay’s brand new book, Find Your Fight , in which Jay teaches the next generation of activists and advocates how to step up and bring about lasting change. You can find Find Your Fight wherever you buy your books, and you can learn more about it at www.jayruderman.com .…

Drug Safety Matters

Udostępnij

Źródło serii•Feed

Drug Safety Matters brings you the best stories from the world of pharmacovigilance. Through in-depth interviews with our guests, we cover new research and trends, and explore the most pressing issues in medicines safety today. Produced by Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring.

53 odcinków

#Science #Fitness #Biology #Medicine #Natural Sciences #Uppsala Monitoring Centre #Drug Safety #Healthcare #Medicines Safety #Patient Safety #Pharmacovigilance #Effect

Drug Safety Matters

updated rok temu

Udostępnij

Źródło serii•Feed

53 odcinków

#Science #Fitness #Biology #Medicine #Natural Sciences #Uppsala Monitoring Centre #Drug Safety #Healthcare #Medicines Safety #Patient Safety #Pharmacovigilance #Effect

Wszystkie odcinki

1
#36 Pregnancy-related pharmacovigilance – Levente Pápai, Lovisa Sandberg & Sara Vidlin 36:44

6 weeks temu36:44

36:44

There are many reasons why use of medical products during pregnancy requires special attention. First and foremost, we want to be sure that the medicine is as safe as possible for both the pregnant person and the unborn child. Unfortunately, the safety profiles of medicines used in pregnancy are often incomplete, which makes it difficult for patients and healthcare professionals to make informed decisions. The Research section at Uppsala Monitoring Centre has a team that is currently focussing their efforts on pregnancy-related pharmacovigilance (PV). In this episode, Data scientists Sara Vidlin and Levente Papai, and Senior Pharmacovigilance scientist Lovisa Sandberg from this team, discuss complexities and challenges of pregnancy-related PV, and new solutions for addressing those challenges. Tune in to find out Why is the world still behind when it comes to pregnancy-related pharmacovigilance? What are the challenges faced by pharmacovigilance assessors wanting to look at pregnancy cases? How can healthcare professionals, patients and carers help assessors overcome these challenges, when reporting pregnancy-related adverse drug events? How can the VigiBase pregnancy algorithm, and other algorithms, support the identification of pregnancy cases? How to use the VigiBase pregnancy algorithm Users of VigiLyze and VigiBase Custom Searches can use the VigiBase pregnancy algorithm as a filter when performing searches. In the qualitative view in VigiLyze, click on “Filter” -> “Patient” -> “Pregnancy” to apply the filter. Want to know more? Read about the VigiBase pregnancy algorithm in this Uppsala Reports article and in this poster , presented at the International Society of Pharmacoepidemiology (ISPE) 2024 annual meeting. EURAP – an international prospective observational study of pregnancies with antiepileptic drugs. EURAP - International Registry of Antiepileptic Drugs and Pregnancy The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) - E2B(R3) Individual Case Safety Report (ICSR) Specification and Related Files: ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files The concePTION project: https://www.imi-conception.eu/ Medical Dictionary for Regulatory Activities (MedDRA®) support documentation: https://www.meddra.org/how-to-use/support-documentation/english Zaccaria C, Piccolo L, Gordillo-Marañón M, et al. Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance. Drug Saf. https://doi.org/10.1007/s4026 Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#35 Veterinary pharmacovigilance part 2 – James Mount 41:42

14 weeks temu41:42

41:42

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous animal species that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. In part 2, you will hear about differences in types of ADRs reported for animals as compared to humans, when humans are accidentally exposed to medicines for animals, and vice versa, how the many species and breeds included in veterinary PV affects the coding of ADR reports, breed-specific ADRs – what is safe for one breed of e.g. dog or pig, may not be appropriate for another, the EU Veterinary Big Data Strategy, ... and much more! Links for further reading The public portal of the European Union Veterinary Pharmacovigilance Database . One Health – an integrated approach to the well-being of people, animals and the environment. A survey of veterinary professionals in Sweden , about practices and attitudes in relation to ADR reporting. A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicines. The EMA Big Data strategy for veterinary medicines . Data quality framework for medicines regulation | European Medicines Agency (EMA) Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool VetCompass - Royal Veterinary College, RVC Reflection paper on the use of artificial intelligence in the lifecycle of medicines | European Medicines Agency (EMA) Veterinary good pharmacovigilance practices (VGVP) | European Medicines Agency (EMA) Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) | European Medicines Agency (EMA) Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#34 Veterinary pharmacovigilance, Part I – James Mount 47:21

20 weeks temu47:21

47:21

Human and veterinary pharmacovigilance (PV) share many goals, challenges and approaches. But there are also significant differences, such as the numerous species and breeds that veterinary PV needs to take into account. In this two-part episode of Drug Safety Matters, James Mount, Veterinary Pharmacovigilance assessor at the Swedish Medical Products Agency, and EU elected chair of the Pharmacovigilance Working Party for veterinary medicinal products, joins the show to talk about veterinary PV practice and its differences and similarities to human PV. Tune in to find out: What are the similarities and differences between veterinary and human pharmacovigilance? How is animal health connected to public health? What types of adverse events are reported on the veterinary side compared with the human side? What can be found in the EU veterinary pharmacovigilance database? Want to know more? The new veterinary medicines regulation (Regulation (EU) 2019/6) can be found here . The public portal of the European Union Veterinary Pharmacovigilance Database . WHO's information page on One Health , an integrated approach to the well-being of people, animals and the environment. A survey of veterinary professionals in Sweden , about current practices and attitudes in relation to adverse events reporting and the accessibility of product safety information. A review of adverse events in animals and children after secondary exposure to transdermal hormone-containing medicinal products. A study looking at suspected adverse drug reaction reporting in veterinary free‐text clinical narratives . The EMA Big Data strategy for veterinary medicines in the EU. Data quality framework for medicines regulation | European Medicines Agency (EMA) Small Animal Veterinary Surveillance Network (SAVSNET) - University of Liverpool VetCompass - Royal Veterinary College, RVC Reflection paper on the use of artificial intelligence in the lifecycle of medicines | European Medicines Agency (EMA) The Swedish Medical Products Agency's online reporting form for suspected adverse drug reactions in animals (In Swedish). Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#33 Narrative fields and signal assessors, an exploratory study – Joana Félix and Alem Zekarias 38:43

23 weeks temu38:43

38:43

While structured data elements such as patient identifier, medicine name and reaction, are fundamental for adverse event reporting, they may not capture all relevant details. This is where the narrative fields come in, allowing reporters to disclose important contextual information, such as the patient’s full clinical course. But how do PV assessors interact with these narratives in spontaneous reports? What needs and challenges do they experience? These and other questions were addressed in an exploratory interview study by UMC researchers Joana Félix and Alem Zekarias. Tune in to find out: What challenges are PV assessors faced with, when working with narratives? How could automation of certain tasks help streamline narrative analyses in the future? How can reporters craft narratives that effectively document adverse events? Want to know more? Pharmacovigilance assessors’ experiences interacting with narrative fields in spontaneous reports: an exploratory interview study – poster presented at the 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics” , 1–5 October 2024 Montreal, Canada. Current Challenges in Pharmacovigilance: Pragmatic Approaches , by The Council for International Organisations of Medical Sciences (CIOMS). See page 133 on the role of narratives in good case management practices. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#32 Pharmacovigilance in older adults – Giovanni Furlan 47:51

28 weeks temu47:51

47:51

Medication-related-harm (MRH) is especially prevalent in older adults due to changing physiology as the body ages, increased frailty, and the incidence of polypharmacy in this patient group. Giovanni Furlan, Worldwide Safety Site Lead for Thessaloniki of Pfizer discusses what makes this patient group so vulnerable to adverse drug reactions, how poor representation and using age alone to define older adults exacerbates this problem, and suggests ways forward in monitoring drug safety in older patients. Tune in to find out: What makes older adults especially at risk of experiencing adverse drug reactions and medication errors Why frailty is far more useful than age in predicting adverse drug reaction risk How pharmacovigilance in older patients may be improved through pharmaceutical practice and better representation in clinical trials. Want to know more? This interview all started with Giovanni's Uppsala Reports article on how age is insufficient a measure of adverse event risk. Read it here . For a summary of the key points discussed in this interview, read Giovanni’s paper on the status of drug safety in geriatric patients . If our discussion of frailty piqued your interest, read this paper on the biology of frailty and how this impacts clinical pharmacology, this multi-centre cohort study that shows frailty is significantly correlated with MRH, and this commentary advocating for consideration of MRH as a geriatric syndrome, which needs to be managed as such. As Giovanni mentioned in the interview, Harlan Krumholz was the first to describe post-hospital syndrome. Learn more about this syndrome by reading his paper . For more on prescribing cascades, their prevention, detection, and reversal, read this paper by Brath and colleagues. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#31 A guide to reporting disproportionality analyses – Michele Fusaroli and Daniele Sartori 42:45

31 weeks temu42:45

42:45

Disproportionality analyses are a mainstay of pharmacovigilance research, but without clear guidelines, they often lead to confusion and misinterpretation. Enter the READUS-PV statement: the first-ever guide for reporting disproportionality analyses that are replicable, reliable, and reproducible. Tune in to find out: The history of reporting guidelines in pharmacovigilance and why the READUS-PV guidelines were created Why there has been a spike in the publication of disproportionality analyses in recent years and what this means for their reliability What it means to publish “good” pharmacovigilance science Want to know more? Read the READUS-PV guidelines , why they were created , and why they are important . In 2021, Khouri and colleagues showed that current methods and models used for disproportionality analyses are unreliable , and Mouffak and colleagues found that there is a tendency to overstate results in published disproportionality analyses . A book on data mining techniques in Pharmacovigilance by Poluzzi and colleagues delves deeper into this exponential increase in disproportionality analyses . This paper elaborates on the Delphi technique, and how it is used to gather data from reviewers to achieve scientific consensus on a problem. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
Uppsala Reports Long Reads – Weeding out duplicates to better detect side effects 25:02

36 weeks temu25:02

25:02

Duplicate reports are a big problem when it comes to signal detection, but with the help of machine learning and new ways of comparing reports, we may more effectively detect them. This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to author Jim Barrett, Senior Data Scientist at UMC, to learn more about the duplicate detection algorithm and UMC’s work to develop AI resources for pharmacovigilance. Tune in to find out: How the new algorithm handles duplicates in VigiBase About different approaches for developing algorithms Why it can be challenging to evaluate the performance of an algorithm Want to know more? Listen to the Drug Safety Matters interview with Michael Glaser about his Uppsala Reports article “Ensuring trust in AI/ML when used in pharmacovigilance” and check out the episode’s extensive list of links for more on AI in pharmacovigilance. Artificial intelligence in pharmacovigilance – value proposition and the need for critical appraisal , a presentation by Niklas Norén, Head of Research at UMC, given at University of Verona in April 2024. Finally, don’t forget to subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
Uppsala Reports Long Reads – Ensuring trust in AI/ML when used in pharmacovigilance 30:18

45 weeks temu30:18

30:18

Ensuring trust in AI is vital to fully reap the benefits of the technology in pharmacovigilance. Yet, how do we do so while grappling with its ever-growing complexity? This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance news site, brought to you in audio format. Find the original article here . After the read, we speak to one of the authors of the article, Michael Glaser, to learn more about how AI and ML has been used in pharmacovigilance so far, and what needs to happen to ensure its continued use in the field. Tune in to find out: ● How AI and ML are being used today in pharmacovigilance processes ● Why a mindset change is necessary to make full use of AI/ML in pharmacovigilance ● How we may best move forward to implement AI/ML into healthcare. Want to know more? To know more about how AI and ML are being used in pharmacovigilance currently, read this scoping review . To know more about future trends of the use of AI in Biopharma, read this Accenture survey . Despite there being major interest in ML and AI to do more than task automation, there are a number of barriers to its implementation in healthcare. Check out this future-focused paper on the use of AI/ML in pharmacovigilance that details how to utilise it to its fullest potential. A mindset shift is necessary in terms of how we think about data, in terms of sharing, how to generate data required to effectively train AI/ML models. A validation framework must be developed for AI-based pharmacovigilance systems . One suggestion is to do so using a risk-based approach . While there is much interest in using recently developed AI technologies such as chatGPT, preliminary studies like this one suggest that the technology has a ways to go to be useful in pharmacovigilance. The World Health Organization have published an extensive guideline on the ethics and governance of AI for health. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#30 Preventing and reporting medication errors – Rabat CC & UMC 33:58

51 weeks temu33:58

33:58

Look-alike medicines, unclear communication and distractions during administration – medication errors may occur for many different reasons. They all have in common that they are unintended mistakes in the drug treatment process that may or may not lead to patient harm. In this episode Ghita Benabdallah and Loubna Alj from the national pharmacovigilance centre of Morocco, and Alem Zekarias from Uppsala Monitoring Centre discuss how we can prevent medication errors from occurring – and, when they do occur, make sure that they are reported as such. Tune in to find out: What are the most common causes for medication errors? How should strategies for preventing medication errors be devised? How does the assessment of suspected medication error reports differ from “regular” ADR signal assessment? What can be done to encourage healthcare professionals to report medication errors? Want to know more? In March 2024, WHO published this systematic review of the global burden of preventable medication-related harm in healthcare. According to this 2021 article in BMJ , an estimated 237 million medication errors occur in England every year. Avoidable adverse drug events were calculated to cost the National Health Service an annual sum of GBP 98 462 582 per year, consuming 181 626 bed-days, and causing/contributing to 1708 deaths. This 2012 meta-analysis confirmed what had been suggested in several observational studies: that preventable adverse drug reactions are a significant healthcare burden. The European Medicines Agency (EMA) has a dedicated webpage with recommendations, guidelines, legal requirements and a good practice guide on medication errors. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#29 When medicines change our behaviour – Michele Fusaroli 30:30

1 year temu30:30

30:30

Medicines can affect our personality in positive ways, but they may also lead to destructive behaviours that can damage our relationships, finances, and overall quality of life. Michele Fusaroli from the University of Bologna explains how to diagnose and treat drug-induced impulse control disorders. Tune in to find out: Which medicines may cause impulsivity What the ‘four knights’ of impulsivity are How patient stories can help detect these conditions Want to know more? This review by Daniel Weintraub summarises twenty years of research on impulse control disorders in Parkinson’s disease. In 2003, Driver-Dunckley and colleagues in the US published the first case series linking pathological gambling to dopamine agonists . In 2016, the US Food and Drug Administration warned about impulse-control problems associated with the antipsychotic drug aripiprazole . Michele and colleagues in Italy have investigated the mechanisms and burden of drug-induced impulsivity. In their 2024 guidelines for managing impulsivity in Parkinson's disease, an expert consensus group highlighted the pivotal role of caregivers and of psychosocial interventions. Finally, these are the Drug Safety Matters episodes cited in the interview: Catching black swans When drugs damage the liver Empowering patients as partners Why we should listen to patients Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#28 Catching black swans – François Montastruc 27:21

1 year temu27:21

27:21

Serious and unexpected adverse drug reactions – the ‘black swans’ of pharmacovigilance – can place enormous strain on safety monitoring systems. Drawing examples from the COVID-19 pandemic, François Montastruc from Toulouse University Hospital explains how we can get better at dealing with the unpredictable. Tune in to find out: What Nassim Nicholas Taleb’s ‘black swan’ theory has to do with pharmacovigilance What makes an adverse drug reaction a black, white, or grey swan Why flexibility and communication are key to patient safety Want to know more? Here are the research articles cited in the episode: Quality of reporting of adverse events in clinical trials of COVID-19 drugs: systematic review Psychiatric disorders and hydroxychloroquine for COVID-19: a VigiBase study Hepatic disorders with the use of remdesivir for COVID-19 Serious bradycardia and remdesivir for COVID-19: a new safety concern Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: a missed opportunity for a rapid return of experience Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: data from the French network of regional pharmacovigilance centres Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: interest of distance learning clinical reasoning sessions If you enjoyed this podcast, check out these related episodes from the Drug Safety Matters archive: Reforming pharmacovigilance education Lessons in pandemic pharmacovigilance Intuition in pharmacovigilance Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#27 When drugs damage the liver – Rita Baião 28:30

1 year temu28:30

28:30

The liver is the primary site for drug metabolism in the body, but it can be severely damaged by medicines or their toxic compounds. Rita Baião from the North Lisbon University Hospital Center reviews what pharmacovigilance professionals should know about drug-induced liver injury (DILI). Tune in to find out: Who is most at risk of developing DILI How to diagnose the condition and control the damage How to assess case reports of DILI Want to know more? This infographic in Nature Reviews nicely summarises the mechanisms, diagnosis, and management of drug-induced liver injury. In this report , the Council for International Organizations of Medical Sciences provides a global perspective on DILI detection, susceptibility factors, outcomes, and more. In this Drug Safety article , industry representatives outline how to identify, mitigate, and communicate the risk of DILI during drug development. The PRO-EURO DILI NETWORK coordinates research efforts on DILI across Europe and provides a forum to exchange knowledge and training on the topic. Similar initiatives include the Spanish DILI Registry and the Latin American DILI Network . The free online tool LiverTox contains up-to-date information on drug-induced liver injury for medicines and herbal products. To learn more about post-marketing surveillance and clinical care of DILI, check out Uppsala Monitoring Centre’s free online course on the topic. For more on the clustering algorithm vigiGroup, revisit this interview with UMC scientists Jim Barrett and Joe Mitchell. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

1
#26 What's trending in pharmacovigilance? – Angela Caro 28:06

1 year temu28:06

28:06

What did the drug safety community achieve in 2023 and how will the field develop in 2024? As the year comes to a close, we asked Angela Caro, president of the International Society of Pharmacovigilance (ISoP), to walk us through current and future trends in pharmacovigilance. Tune in to find out: Why patient engagement is a growing priority What challenges exist in the Latin American region Which topics will be in the spotlight next year Want to know more? ISoP is a non-profit society open to anyone with an interest in pharmacovigilance. Through 14 chapters and 13 special interest groups , the society works to enhance the safe and proper use of medicines across countries. Their latest annual meeting took place in Bali, Indonesia in November 2023, while the next one will take place in Montreal, Canada in October 2024. To learn more about ISoP’s activities in patient engagement and pharmacogenomics, listen to these episodes from the Drug Safety Matters archive: Empowering patients as partners Tailoring drug therapy to your genes Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

3 years temu25:08

25:08

The loss of vital health records is a universal problem for refugees. When their medical information goes missing, patients are less likely to receive the care they need and more likely to be prescribed the wrong treatments. Thankfully, the International Society of Pharmacovigilance Egypt Chapter and the Palestine Red Crescent Society are taking on this problem, to reduce medication errors and improve reporting practices. This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance magazine, brought to you in audio format. Find the original article here . After the read, we speak to Mohamed Elhawary and Hadir Rostom, who co-authored the article, to learn more about their work and the overall challenge of ensuring medicines safety in vulnerable communities. Tune in to find out: What the most frequent causes of medication errors in refugee communities are How electronic health records can help prevent harm to patients Why safety monitoring is crucial when there is a shortage of medicines Want to know more? The International Society of Pharmacovigilance runs a Special Interest Group on medication errors to promote the implementation of best safety practices around the world. They also organise a range of networking and training activities for pharmacovigilance professionals on different aspects of medicines safety. The United Nations High Commissioner for Refugees (UNHCR) has practical advice for healthcare workers to promote treatment adherence in refugee settings . Finally, don’t forget to subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on X , LinkedIn , or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch ! About UMC Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.…

Zapraszamy w Player FM

Odtwarzacz FM skanuje sieć w poszukiwaniu wysokiej jakości podcastów, abyś mógł się nią cieszyć już teraz. To najlepsza aplikacja do podcastów, działająca na Androidzie, iPhonie i Internecie. Zarejestruj się, aby zsynchronizować subskrypcje na różnych urządzeniach.